angiotensin ii has been researched along with linagliptin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, F; Li, XW; McKallip, RJ; Pang, XF; Shah, AI; Wang, NP; Wang, X; Zhang, LH; Zhao, ZQ | 1 |
| Abouelkheir, M; El-Metwally, TH | 1 |
| Bai, F; Banks, TE; Rajapaksha, M; Wang, NP; Zhang, LH; Zhao, ZQ | 1 |
3 other study(ies) available for angiotensin ii and linagliptin
| Article | Year |
|---|---|
Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Collagen; Fibrosis; Gene Expression; Glucagon-Like Peptide 1; Linagliptin; Liraglutide; Male; Myocardium; Peptidyl-Dipeptidase A; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Smad Proteins; Transforming Growth Factor beta1 | 2015 |
Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enalapril; Female; Glucagon-Like Peptide 1; Humans; Hypertension; Linagliptin; Peptidyl-Dipeptidase A; Protein Binding; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate | 2019 |
Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.
Topics: Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Glucagon-Like Peptide 1; Hypertension; Linagliptin; Liraglutide; Mitochondria; NADPH Oxidase 4; Rats; Rats, Sprague-Dawley | 2022 |